Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Suspended 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ureteral Neoplasms 2Carcinoma, Transitional Cell 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Disease 1

Interventions

Gemcitabine 8pembrolizumab 5Cisplatin 5enfortumab vedotin 3avelumab 3Specimen Handling 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3vinflunine 2Radiotherapy 2Nephroureterectomy 2Immunoglobulin G 2Doxorubicin 2Disulfides 2vandetanib 1tremelimumab 1tocilizumab 1tamibarotene 1relatlimab 1pegfilgrastim 1merphos 1guadecitabine 1genexol-PM 1enzalutamide 1durvalumab 1dehydroftorafur 1atezolizumab 1abexinostat 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Ureteral Neoplasms × Nephroureterectomy × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02607709 2024-01-30

Lymphadenectomy in Urothelial Carcinoma

Zealand University Hospital

Phase NA Suspended
366 enrolled

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡